Amanda Jane Leach1,2, Edward Kim Mulholland3,4, Mathuram Santosham5, Paul John Torzillo6,7, Peter McIntyre8, Heidi Smith-Vaughan9,10, Nicole Wilson9,10, Beth Arrowsmith9,10, Jemima Beissbarth9,10, Mark D Chatfield9,10,11, Victor M Oguoma9,10,12, Peter Stanley Morris9,10,13. 1. Child Health Division, Menzies School of Heath Research, Casuarina, Northern Territory, Australia. amanda.leach@menzies.edu.au. 2. Charles Darwin University, Casuarina, Northern Territory, Australia. amanda.leach@menzies.edu.au. 3. Murdoch Children's Research Institute, Department of Paediatrics, University of Melbourne, Melbourne, Australia. 4. London School of Hygiene and Tropical Medicine, London, UK. 5. Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. 6. Prince Alfred Hospital, Sydney, NSW, Australia. 7. University of Sydney, NSW, Australia. 8. National Centre for Immunization Research and Surveillance, Sydney, NSW, Australia. 9. Child Health Division, Menzies School of Heath Research, Casuarina, Northern Territory, Australia. 10. Charles Darwin University, Casuarina, Northern Territory, Australia. 11. Centre for Health Services Research Faculty of Medicine, University of Queensland, Brisbane QLD, Australia. 12. Health Research Institute University of Canberra, Canberra, ACT, Australia. 13. Department of Paediatrics , Royal Darwin Hospital, Darwin, Northern Territory, Australia.
Abstract
BACKGROUND:Aboriginal children living in Australian remote communities are at high risk of early and persistent otitis media, hearing loss, and social disadvantage. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are the primary pathogens. We compared otitis media outcomes in infants randomised to either a combination of Synflorix™ (PHiD-CV10, with protein D of NTHi) and Prevenar13™ (PCV13, with 3, 6A, and 19A), with recommended schedules for each vaccine alone. We previously reported superior broader overall immunogenicity of the combination schedule at 7 months, and early superiority of PHiD-CV10 compared to PCV13 at 4 months. METHODS: In an open-label superiority trial, we randomised (1:1:1) Aboriginal infants at 28 to 38 days of age, to either Prevenar13™ (P) at 2-4-6 months (_PPP), Synflorix™ (S) at 2-4-6 months (_SSS), or Synflorix™ at 1-2-4 months plus Prevenar13™ at 6 months (SSSP). Ears were assessed using tympanometry at 1 and 2 months, combined with otoscopy at 4, 6, and 7 months. A worst ear diagnosis was made for each child visit according to a severity hierarchy of normal, otitis media with effusion (OME), acute otitis media without perforation (AOMwoP), AOM with perforation (AOMwiP), and chronic suppurative otitis media (CSOM). RESULTS:Between September 2011 and September 2017, 425 infants were allocated to _PPP(143), _SSS(141) or SSSP(141). Ear assessments were successful in 96% scheduled visits. At 7 months prevalence of any OM was 91, 86, and 90% in the _PPP, _SSS, and SSSP groups, respectively. There were no significant differences in prevalence of any form of otitis media between vaccine groups at any age. Combined group prevalence of any OM was 43, 57, 82, 87, and 89% at 1, 2, 4, 6, and 7 months of age, respectively. Of 388 infants with ear assessments at 4, 6 and 7 months, 277 (71.4%) had OM that met criteria for specialist referral; rAOM, pOME, or CSOM. CONCLUSIONS: Despite superior broader overall immunogenicity of the combination schedule at 7 months, and early superiority of PHiD-CV10 compared to PCV13 at 4 months, there were no significant differences in prevalence of otitis media nor healthy ears throughout the first months of life. TRIAL REGISTRATION: ACTRN12610000544077 registered 06/07/2010 and ClinicalTrials.gov NCT01174849 registered 04/08/2010.
RCT Entities:
BACKGROUND: Aboriginal children living in Australian remote communities are at high risk of early and persistent otitis media, hearing loss, and social disadvantage. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are the primary pathogens. We compared otitis media outcomes in infants randomised to either a combination of Synflorix™ (PHiD-CV10, with protein D of NTHi) and Prevenar13™ (PCV13, with 3, 6A, and 19A), with recommended schedules for each vaccine alone. We previously reported superior broader overall immunogenicity of the combination schedule at 7 months, and early superiority of PHiD-CV10 compared to PCV13 at 4 months. METHODS: In an open-label superiority trial, we randomised (1:1:1) Aboriginal infants at 28 to 38 days of age, to either Prevenar13™ (P) at 2-4-6 months (_PPP), Synflorix™ (S) at 2-4-6 months (_SSS), or Synflorix™ at 1-2-4 months plus Prevenar13™ at 6 months (SSSP). Ears were assessed using tympanometry at 1 and 2 months, combined with otoscopy at 4, 6, and 7 months. A worst ear diagnosis was made for each child visit according to a severity hierarchy of normal, otitis media with effusion (OME), acute otitis media without perforation (AOMwoP), AOM with perforation (AOMwiP), and chronic suppurative otitis media (CSOM). RESULTS: Between September 2011 and September 2017, 425 infants were allocated to _PPP(143), _SSS(141) or SSSP(141). Ear assessments were successful in 96% scheduled visits. At 7 months prevalence of any OM was 91, 86, and 90% in the _PPP, _SSS, and SSSP groups, respectively. There were no significant differences in prevalence of any form of otitis media between vaccine groups at any age. Combined group prevalence of any OM was 43, 57, 82, 87, and 89% at 1, 2, 4, 6, and 7 months of age, respectively. Of 388 infants with ear assessments at 4, 6 and 7 months, 277 (71.4%) had OM that met criteria for specialist referral; rAOM, pOME, or CSOM. CONCLUSIONS: Despite superior broader overall immunogenicity of the combination schedule at 7 months, and early superiority of PHiD-CV10 compared to PCV13 at 4 months, there were no significant differences in prevalence of otitis media nor healthy ears throughout the first months of life. TRIAL REGISTRATION: ACTRN12610000544077 registered 06/07/2010 and ClinicalTrials.gov NCT01174849 registered 04/08/2010.
Authors: Hasantha Gunasekera; Stephanie Knox; Peter Morris; Helena Britt; Peter McIntyre; Jonathan C Craig Journal: Pediatr Infect Dis J Date: 2007-08 Impact factor: 2.129
Authors: Michael J Binks; Allen C Cheng; Heidi Smith-Vaughan; Theo Sloots; Michael Nissen; David Whiley; Joseph McDonnell; Amanda J Leach Journal: BMC Infect Dis Date: 2011-06-07 Impact factor: 3.090
Authors: Jiunn-Yih Su; Vincent Yaofeng He; Steven Guthridge; Damien Howard; Amanda Leach; Sven Silburn Journal: Aust N Z J Public Health Date: 2019-10-30 Impact factor: 2.939
Authors: Tal Marom; Alai Tan; Gregg S Wilkinson; Karen S Pierson; Jean L Freeman; Tasnee Chonmaitree Journal: JAMA Pediatr Date: 2014-01 Impact factor: 16.193
Authors: Jiunn-Yih Su; Steven Guthridge; Vincent Yaofeng He; Damien Howard; Amanda Jane Leach Journal: BMC Public Health Date: 2020-10-07 Impact factor: 3.295